Glutathione — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Endogenous tripeptide antioxidant (Glu-Cys-Gly)
Reported half-life: Minutes intravenously
Routes used in the literature: Intravenous, inhaled, oral and liposomal in published studies
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Intravenous studies in Parkinson's disease

Reported quantity: 600–1400 mg per infusion
Frequency: Three times weekly
Study duration: 4 weeks to 6 months

The larger randomised study did not show a meaningful benefit over placebo.

Oral and liposomal supplementation trials

Reported quantity: 250–1000 mg per day
Frequency: Once or twice daily
Study duration: 4–24 weeks

Liposomal formulations raise blood levels where standard oral forms largely do not.

Dermatological skin-lightening studies

Reported quantity: 500 mg orally daily, or 250 mg intravenously weekly
Frequency: Daily or weekly
Study duration: 4–12 weeks

Several regulators, including the Philippine FDA, have warned specifically about intravenous use for this purpose.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

Glutathione · 600 mg Vial

Glutathione is dosed at 100 mg–200 mg daily via subcutaneous injection in educational protocols. A 600 mg vial reconstituted with bacteriostatic water yields about 300 mg/mL. This information is for research and educational use only.

Reconstitute: Add 2.0 mL bacteriostatic water → 300 mg/mL concentration.
Typical daily range: 100–200 mg subcutaneously (gradual titration recommended).
Easy measuring: At 300 mg/mL, 1 unit = 0.01 mL = 3 mg on a U-100 insulin syringe.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Standard / Gradual Approach (2 mL = 300 mg/mL)

Week	Daily Dose (mg)	Units (per injection) (mL)
Weeks 1–2	100 mg	33 units (0.33 mL)
Weeks 3–4	150 mg	50 units (0.50 mL)
Weeks 5–8	200 mg	67 units (0.67 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size Glutathione is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

Glutathione · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	100 mg =	200 mg =
500 mg	166.67 mg/ml	1,667 mcg	60 units	120 units
1500 mg	500.00 mg/ml	5,000 mcg	20 units	40 units

Unit columns use the range reported for this compound (100 mg–200 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

Commonly supplied as 200 mg/mL solution or as a lyophilised 600 mg vial; 600 mg in 6 mL gives 100 mg/mL.

Open the reconstitution calculator

How to read these figures

Intravenous use for cosmetic skin-lightening has attracted explicit regulatory warnings.
Standard oral glutathione is largely broken down before absorption — form matters more than quantity.
The Parkinson's literature is a case study in a promising open-label result failing a controlled trial.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine
Aebi S, Assereto R, Lauterburg BH. · European Journal of Clinical Investigation · 1991 · PMID 1907548
Ten healthy volunteers received high-dose intravenous reduced glutathione infusions to characterize pharmacokinetics and effects on plasma/urine cysteine.
View the record
[2]
Reduced intravenous glutathione in the treatment of early Parkinson's disease
Sechi G, Deledda MG, Bua G, et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 1996 · PMID 8938817
Patients with early Parkinson's disease received intravenous reduced glutathione (600 mg twice daily) over a 30-day period to assess clinical effects on motor symptoms.
View the record
[3]
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser RA, Lyons KE, McClain T, et al. · Movement Disorders · 2009 · DOI 10.1002/mds.22401
Parkinson's disease patients were randomized to intravenous glutathione infusions three times weekly for four weeks in a placebo-controlled pilot trial.
View the record

Search the databases yourself

Read the Glutathione research brief

Other longevity compounds

CartalaxSynthetic tripeptide (Ala-Glu-Asp) bioregulator EpithalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly)FOXO4-DRIFOXO4-p53 interaction-disrupting retro-inverso peptide Humanin24-amino-acid mitochondrial-derived peptide

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.